Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Doxorubicin
Drug ID BADD_D00723
Description Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix.
Indications and Usage Doxorubicin is used to produce regression in disseminated neoplastic conditions like acute lymphoblastic leukemia, acute myeloblastic leukemia, Wilms’ tumor, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, ovarian carcinoma, transitional cell bladder carcinoma, thyroid carcinoma, gastric carcinoma, Hodgkin’s disease, malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types. Doxorubicin is also indicated for use as a component of adjuvant therapy in women with evidence of axillary lymph node involvement following resection of primary breast cancer.
Marketing Status Prescription; Discontinued
ATC Code L01DB01
DrugBank ID DB00997
KEGG ID D03899
MeSH ID D004317
PubChem ID 31703
TTD Drug ID D07VLY
NDC Product Code 72027-002; 12543-3209; 70121-1218
Synonyms Doxorubicin | Farmiblastina | Ribodoxo | Rubex | Adriamycin | Adriblastin | Adriblastine | Adriblastina | Adriablastine | Adriablastin | Adrimedac | DOXO-cell | DOXO cell | Urokit Doxo-cell | Urokit Doxo cell | Doxolem | Doxorubicin Hexal | Doxorubicin Hydrochloride | Hydrochloride, Doxorubicin | Doxorubicin NC | Doxorubicina Ferrer Farm | Doxorubicina Funk | Doxorubicina Tedec | Doxorubicine Baxter | Doxotec | Myocet | Onkodox
Chemical Information
Molecular Formula C27H29NO11
CAS Registry Number 23214-92-8
SMILES CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
CardiotoxicityTroponin I, fast skeletal muscleP48788Not Available11535996; 11109196; 10076722
CardiotoxicityCreatine kinase B-typeP07335Not Available26036690
Cell deathCaspase-3P42574T57943Not Available
Cytogenetic investigationsDNA topoisomerase 1P11387T098261997159; 1649059; 1333822; 1540962; 1596908; 1330289; 8382551; 2168279; 2168281; 1319346; 11062742; 1374671; 1646393; 7882360; 1322239; 7688316; 1659821; 8383887; 8144400; 1698546
Electrolyte imbalanceParathyroid hormone/parathyroid hormone-related peptide receptorQ03431T677108400511; 1392187; 6853131; 820624; 1169899; 231063; 6691353; 2995735
Electrolyte imbalanceOsteocalcinP02818Not Available8400511; 1392187; 6853131; 820624; 1169899; 231063; 6691353; 2995735
Myocardial disordersCaspase-3P70677Not Available25657296
Renal tubular disorderBeta-hexosaminidase subunit alphaP06865Not Available1658168; 1940584; 1436313; 7977444; 2848972; 3123518; 2831737; 6434591; 2843051; 2118039; 2460571; 1960147; 16171782; 1324141; 8160791; 8070692; 2601299; 2176953; 10416216; 2156648
Renal tubular disorderLysozyme CP61626T105861658168; 1940584; 1436313; 7977444; 2848972; 3123518; 2831737; 6434591; 2843051; 2118039; 2460571; 1960147; 16171782; 1324141; 8160791; 8070692; 2601299; 2176953; 10416216; 2156648
Skin toxicityGlutathione peroxidase 3P23764Not Available11154863
Skin toxicityPeroxiredoxin-5, mitochondrialP30044T7700911154863; 9726807; 12566827; 11594740; 11330521; 14535831; 12718433; 12751907; 9726810; 11529555
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Cystitis haemorrhagic20.03.02.003--Not Available
Deafness04.02.01.0010.000799%Not Available
Death08.04.01.001--
Decubitus ulcer23.03.11.0060.000533%Not Available
Dehydration14.05.05.0010.005062%
Delirium19.13.02.001--
Depression19.15.01.001--
Dermatitis23.03.04.0020.001332%Not Available
Dermatitis atopic23.03.04.016; 10.01.04.004--Not Available
Dermatitis bullous23.03.01.002--
Dermatitis contact23.03.04.004; 12.03.01.040; 10.01.01.003--Not Available
Dermatitis exfoliative10.01.01.004; 23.03.07.0010.000533%
Diabetes insipidus14.05.07.003; 05.03.03.0040.000799%Not Available
Diabetes mellitus14.06.01.001; 05.06.01.001--Not Available
Diarrhoea07.02.01.001--
Diarrhoea haemorrhagic07.02.01.002; 24.07.02.004--Not Available
Dilatation ventricular02.04.02.0260.000799%Not Available
Diplopia17.17.01.005; 06.02.06.002--Not Available
Discomfort08.01.08.003--Not Available
Disorientation19.13.01.002; 17.02.05.015--Not Available
Disseminated intravascular coagulation01.01.02.002; 24.01.01.0100.000533%
Disturbance in attention19.21.02.002; 17.03.03.001--
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.004--
Drug hypersensitivity10.01.01.001--Not Available
Dry eye06.08.02.001--
Dry mouth07.06.01.002--
Dry skin23.03.03.0010.001865%
Dysaesthesia17.02.06.003--
Dysarthria19.19.03.001; 17.02.08.001--
Dysgeusia17.02.07.003; 07.14.03.001--
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 25 Pages